Tag: NEJM
-
Long-Term Combined Plavix – Effient Use May Be Associated With An Increased Overall Risk Of Non-Cardiovascular Death Compared To Shorter Therapy Period
FDA Drug Safety Communication Issued In November 2014 About The Dual Antiplatelet Therapy (DAPT) Trial Which Was Published In The New England Journal of Medicine (Posted by Tom Lamb at DrugInjuryWatch.com)Plavix (clopidogrel) and…
-
Generic Drugs Post-Mensing Ruling: One Proposed Solution To The Legal Compensation And FDA Drug Safety Problems Supreme Court Created
At Least, This November 2012 Article In The New England Journal Of Medicine Makes The Point That Something Needs To Be Done Soon, Rather Than Later (Posted by Tom Lamb at DrugInjuryWatch.com) The June 2011…
-
Study About Using Glaxo’s Avodart To Prevent Prostate Cancer Finds Possible Heart Risk
Higher Rate Of Cardiac Failure In Men Taking Avodart (Dutasteride) – 0.7 Percent vs. 0.4 Percent For Those Taking The Placebo (Posted by Tom Lamb at DrugInjuryWatch.com) In the April 1, 2010 edition of…
-
Aranesp Associated With Increased Risk For Stroke In Patients With Diabetes And Chronic Kidney Disease
TREAT Study Revealed, Also, That This Amgen Anemia Drug Was No Better Than Placebo In Reducing Deaths Or Cardiovascular Problems (Posted by Tom Lamb at DrugInjuryWatch.com) The anemia drug Aranesp (darbepoetin alfa) might cause an increased…